Effects of pretherapy variations in Cbl, MMA, and HCys on patient classification
. | . | Second pretherapy value, no. (%) . | . | |
|---|---|---|---|---|
| Measurement . | No. with 1 normal pretherapy value* . | Normal . | Abnormal . | |
| Cbl | 181 | 93 (51) | 88† (49) | |
| MMA | 51 | 32 (63) | 19‡ (37) | |
| HCys | 57 | 42 (74) | 15§ (26) | |
. | . | Second pretherapy value, no. (%) . | . | |
|---|---|---|---|---|
| Measurement . | No. with 1 normal pretherapy value* . | Normal . | Abnormal . | |
| Cbl | 181 | 93 (51) | 88† (49) | |
| MMA | 51 | 32 (63) | 19‡ (37) | |
| HCys | 57 | 42 (74) | 15§ (26) | |
Normal values were defined as follows: Cbl, greater than 300 pg/mL; MMA, less than 251 nmol/L; HCys, less than 12.2 μmol/L.
Includes all patients tested on 2 occasions within 6 weeks. Either the initial or repeat test result was within the normal range.
Includes 8 patients with Cbl values less than 201 pg/mL (4%).
Includes 3 patients with MMA values greater than 376 nmol/L (6%).
Includes 8 patients with HCys values greater than 13.6 μmol/L (14%).